NVCR - NovoCure Ltd

13.42
0.120   0.894%

Share volume: 1,702,167
Last Updated: 03-04-2026
Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies: -0.01%

PREVIOUS CLOSE
CHG
CHG%
$13.30
0.12
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
44%
Profitability 25%
Dept financing 47%
Liquidity 75%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.74%
1 Month
33.00%
3 Months
10.82%
6 Months
9.28%
1 Year
-29.92%
2 Year
-17.67%
Key data
Stock price
$13.42
P/E Ratio 
0.00
DAY RANGE
$12.79 - $13.51
EPS 
-$1.22
52 WEEK RANGE
$9.82 - $21.55
52 WEEK CHANGE
-$30.32
MARKET CAP 
1.448 B
YIELD 
N/A
SHARES OUTSTANDING 
113.794 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-24-2025
BETA 
2.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,209,577
AVERAGE 30 VOLUME 
$3,253,429
Company detail
CEO: Asaf Danziger
Region: US
Website: novocure.com
Employees: 1,320
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing

NovoCure Limited engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma.

Recent news